Live Chat ×
Skip to main content

Case Discussions on Improving Outcomes in Neovascular AMD: Applying Research to Practice - Tuesday, November 10, 2020


CME Webinar

Tuesday, November 10, 2020
7:00 PM PST | 8:00 PM MST | 9:00 PM CST | 10:00 PM EST  


NOTE: You will be asked to "sign in" or "sign up" to register for the program and then complete a brief pretest. Once you submit your answers, choose "next item". Upon registration, a link to access the webinar will be sent in a confirmation email.

Please contact ksponza@mededicus.com with any questions. Thank you!

FACULTY

David Eichenbaum, MD (Co-Chair)
Collaborative Associate Professor of Ophthalmology
Morsani College of Medicine
University of South Florida
Partner and Director of Research
Retina Vitreous Associates of Florida
Tampa, Florida

Charles C. Wykoff, MD, PhD (Co-Chair)
Director of Research
Retina Consultants of Houston
Deputy Chair for Ophthalmology
Blanton Eye Institute
Houston Methodist Hospital
Houston, Texas

CONTINUING MEDICAL EDUCATION INFORMATION

Learning Method and Medium
This educational activity consists of a six (6)-question pretest, a webinar, and three (3) study questions. The participant should, in order, read the learning objectives, complete the pretest, participate in the webinar, answer all questions in the post test, and complete the evaluation. To receive credit for this activity, please complete the post test and evaluation. This educational activity should take a maximum of 1.5 hours to complete.

Activity Description and Purpose

Although the treatment of neovascular age-related macular degeneration (nAMD) has made significant strides in the last several years, long-term visual acuity potential among affected populations still suffers due to delayed diagnosis and a high treatment burden leading to suboptimal patient adherence. Research demonstrates that earlier diagnosis of conversion from dry to wet age-related macular degeneration results in the best long-term visual outcomes. Although fixed, frequent dosing is also the gold standard for achieving and maintaining the best possible vision, accumulating research demonstrates that individualized dosing according to disease activity and fluid type can reduce the burden of treatment while maintaining vision. This approach is predicated on careful monitoring of retinal fluid on optical coherence tomography, which has been complicated by the coronavirus disease 2019 pandemic. Home monitoring of fluid dynamics has the potential to identify disease activity in real time while keeping vulnerable patients safer at home. In addition, newer anti–vascular endothelial growth factor agents have prolonged action, potentially enabling fewer injection visits compared with older agents. In this educational activity, experts in nAMD will discuss strategies for reducing the treatment burden in nAMD while identifying and treating fluid in an individualized manner. The desired results of this educational activity are for retina specialists and other ophthalmologists to use evidence-based diagnostic and treatment strategies for nAMD that minimize treatment burden while maximizing vision and quality of life outcomes for patients.

Target Audience
This educational activity is intended for retina specialists and other ophthalmologists who treat patients with neovascular age-related macular degeneration.

Learning Objectives
Upon completion of this activity, participants will be better able to:
  • Design and implement strategies for earlier diagnosis of conversion from dry to wet age-related macular degeneration
  • Interpret comparative clinical trial data for approved treatments for neovascular age-related macular degeneration
  • Develop individualized treatment strategies for patients with neovascular age-related macular degeneration that optimize efficacy and safety while minimizing injection burden
  • Incorporate recent clinical trial data into communication strategies to enhance patient adherence to treatment for neovascular age-related macular degeneration

Accreditation Statement
The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.

AMA Credit Designation Statement
The New York Eye and Ear Infirmary of Mount Sinai designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grantor Statement
This continuing medical education activity is supported through unrestricted educational grants from Novartis Pharmaceuticals Corporation and Notal Vision, Inc.

Disclosure Policy Statement
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

Disclosures
David Eichenbaum, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; EyePoint Pharmaceuticals; Genentech, Inc; Gyroscope; Kodiak Sciences Inc; and Regeneron Pharmaceuticals, Inc; Contracted Research: Alkahest, Inc; Allergan; Chengdu Kanghong Pharmaceutical Group Co Ltd; Gemini Therapeutics; Genentech, Inc; Gyroscope; Ionis Pharmaceuticals, Inc; IVERIC Bio; Kodiak Sciences Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals, Inc; and Santen Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; EyePoint Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Clearside Biomedical, Inc; and Hemera Biosciences.

Charles C. Wykoff, MD, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Acucela Inc; Adverum; Alcon; Alimera Sciences; Allergan; Apellis Pharmaceuticals; Arctic Vision (Shanghai) Biotechnology Co, Ltd; Bausch & Lomb Incorporated; Bayer Corporation; Bionic Vision Technologies; Chengdu Kanghong Pharmaceutical Group Co Ltd; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.; F. Hoffmann-La Roche Ltd; Genentech, Inc; Gyroscope; IVERIC Bio; Kodiak Sciences Inc; Merck & Co., Inc; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; ONL Therapeutics; Opthea; Oxurion NV; Palatin Technologies, Inc; PolyPhotonix; Recens Medical, Inc; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Takeda Pharmaceuticals USA, Inc; and Thea Pharmaceuticals Limited; Contracted Research: Adverum; Aerie Pharmaceuticals, Inc; Aldeyra Therapeutics; Apellis Pharmaceuticals; Boehringer Ingelheim International GmbH; Chengdu Kanghong Pharmaceutical Group Co Ltd; Clearside Biomedical, Inc; F. Hoffmann-La Roche Ltd; Gemini Therapeutics; Genentech, Inc; GrayBug, Inc; Gyroscope; Ionic Pharmaceuticals, Inc; IVERIC bio; Kodiak Sciences Inc; Neurotech Pharmaceuticals; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Opthea; Outlook Therapeutics, Inc; Recens Medical, Inc; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Santen Inc; Senju Pharmaceutical Co, Ltd; Taiwan Liposome Company, Ltd; and Xbrane Biopharma AB; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Regeneron Pharmaceuticals, Inc.

New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure

Gennady Landa, MD, has no relevant commercial relationships to disclose.

Editorial Support Disclosures
Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.

Disclosure Attestation
The contributing physicians listed above have attested to the following:
  1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
  2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
  3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

Off-Label Discussion
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
https://www.nyee.edu/education/cme

CME Provider Contact Information
For questions about this activity, call 917-270-7571.

To Obtain AMA PRA Category 1 Credit
To obtain AMA PRA Category 1 Credit™ for this activity, complete the pretest, participate in the webinar, and complete the post test and evaluation. Upon completion, your certificate will be made available online and you can print it or file it.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Novartis Pharmaceuticals Corporation, or Notal Vision, Inc.

This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 232